GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cassava Sciences Inc (NAS:SAVA) » Definitions » Shiller PE Ratio

Cassava Sciences (Cassava Sciences) Shiller PE Ratio

: (As of Today)
View and export this data going back to 2000. Start your Free Trial

Shiller PE for Stocks: The True Measure of Stock Valuation


Cassava Sciences Shiller PE Ratio Historical Data

The historical data trend for Cassava Sciences's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cassava Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Cassava Sciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison

For the Biotechnology subindustry, Cassava Sciences's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cassava Sciences Shiller PE Ratio Distribution

For the Biotechnology industry and Healthcare sector, Cassava Sciences's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Cassava Sciences's Shiller PE Ratio falls into.



Cassava Sciences Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Cassava Sciences's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, Cassava Sciences's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.5/129.4194*129.4194
=-0.500

Current CPI (Dec. 2023) = 129.4194.

Cassava Sciences Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 -0.560 99.695 -0.727
201406 -0.490 100.560 -0.631
201409 -0.560 100.428 -0.722
201412 -0.350 99.070 -0.457
201503 -0.420 99.621 -0.546
201506 -0.490 100.684 -0.630
201509 -0.560 100.392 -0.722
201512 -0.700 99.792 -0.908
201603 -0.910 100.470 -1.172
201606 -0.460 101.688 -0.585
201609 -0.540 101.861 -0.686
201612 -0.420 101.863 -0.534
201703 -0.420 102.862 -0.528
201706 -0.640 103.349 -0.801
201709 -0.400 104.136 -0.497
201712 -0.370 104.011 -0.460
201803 -0.330 105.290 -0.406
201806 -0.360 106.317 -0.438
201809 -0.110 106.507 -0.134
201812 -0.040 105.998 -0.049
201903 -0.080 107.251 -0.097
201906 -0.060 108.070 -0.072
201909 -0.040 108.329 -0.048
201912 -0.080 108.420 -0.095
202003 -0.050 108.902 -0.059
202006 -0.050 108.767 -0.059
202009 -0.060 109.815 -0.071
202012 -0.090 109.897 -0.106
202103 -0.090 111.754 -0.104
202106 -0.130 114.631 -0.147
202109 -0.240 115.734 -0.268
202112 -0.350 117.630 -0.385
202203 -0.440 121.301 -0.469
202206 -0.480 125.017 -0.497
202209 -0.510 125.227 -0.527
202212 -0.470 125.222 -0.486
202303 -0.580 127.348 -0.589
202306 -0.630 128.729 -0.633
202309 -0.610 129.860 -0.608
202312 -0.500 129.419 -0.500

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Cassava Sciences  (NAS:SAVA) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Cassava Sciences Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Cassava Sciences's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Cassava Sciences (Cassava Sciences) Business Description

Traded in Other Exchanges
Address
6801 N. Capital of Texas Highway, Suite 300, Building 1, Austin, TX, USA, 78731
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms.
Executives
Sanford Robertson director ONE LETTERMAN DRIVE, BUILDING C SUITE 410, SAN FRANCISCO CA 94129
Richard Barry director 285 MARGALITA DRIVE, SAN RAFAEL CA 94901
Robert Christopher Cook officer: SVP & General Counsel 6801 N. CAPITAL OF TEXAS HWY, BUILDING 1, SUITE 300, AUSTIN TX 78731
James William Kupiec officer: Chief Clinical Dev. Officer 7801 N CAPITAL OF TEXAS HIGHWAY, SUITE 260, AUSTIN TX 78731
Eric Schoen officer: Chief Financial Officer 7801 N. CAPITAL OF TX HWY, SUITE 260, AUSTIN TX 78731
Remi Barbier director, 10 percent owner, officer: CEO, Chairman of the Board
Armistice Capital Master Fund Ltd. 10 percent owner C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Armistice Capital, Llc 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Steven Boyd 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
O Donnell Michael J director
Robert Z Gussin director
Scannon Patrick J Md Phd director C/O XOMA, LTD., 2910 SEVENTH STREET, BERKELEY CA 94710
Saira Ramasastry director 501 CANAL BLVD., RICHMOND CA 94804
Nadav Friedmann director, officer: Chief Scientific Officer
Sabretooth Master Fund, L.p. 10 percent owner 405 LEXINGTON AVENUE, 50TH FLOOR, NEW YORK NY 10174